SOMATULINE DEPOT

LOE ApproachingPeptide

lanreotide acetate

Ipsen
NDASUBCUTANEOUSSOLUTION
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1

Clinical Trials (1)

NCT00774930Phase 3Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Started May 2009
115 enrolled
Carcinoid Syndrome
Company
Ipsen
Ipsen
China - Tianjin
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers